A360
Key Takeaways✦ Atlas AI
01
A recent study suggests that using apoB testing to guide cholesterol treatment could prevent more cardiovascular events and be cost-effective compared to current standard methods, offering a more precise risk assessment.
02
ApoB testing, despite its potential to more accurately reflect cardiovascular risk, faces barriers to widespread adoption due to additional costs, the need for another blood test, and limited clinician awareness.
03
Upcoming 2026 dyslipidemia guidelines will acknowledge apoB's superior risk reflection and support its use, signaling a potential shift towards more precise cardiovascular risk management in clinical practice.
Atlas AI
Apolipoprotein B (apoB) testing may help clinicians guide cholesterol-lowering treatment in a way that prevents more heart attacks and strokes than strategies based on standard markers such as LDL cholesterol or non-HDL cholesterol, according to a recent study. The analysis also suggests the approach could be cost-effective.
Why apoB may better capture cardiovascular risk
Routine cholesterol assessment often relies on LDL (“bad cholesterol”) and non-HDL cholesterol to estimate risk and decide when to start or intensify therapy. However, these measures do not directly count the number of harmful cholesterol-carrying particles in the blood.
ApoB is the primary component of these atherogenic (“bad”) particles, so measuring apoB may provide a more direct proxy for particle number—and, the study argues, a more precise reflection of cardiovascular risk than LDL or non-HDL cholesterol alone.
Limited use in routine care
Despite growing evidence, apoB testing is not widely used in everyday clinical practice. The article notes several reasons, including that apoB typically requires an additional blood test beyond a standard lipid panel, modest extra costs, and limited awareness among clinicians.
The landscape may be shifting. The upcoming 2026 multi-society dyslipidemia guidelines are described as acknowledging apoB as a superior reflection of cardiovascular risk. While they support apoB testing, they do not yet position apoB as the primary goal for treatment intensification.
What the study modeled
The study used a simulation model of 250,000 adults who were eligible for cholesterol-lowering therapy. Researchers compared treatment strategies guided by LDL cholesterol targets, non-HDL cholesterol targets, and apoB targets.
In the model, treatment intensification guided by apoB targets was associated with fewer projected cardiovascular events over time than approaches guided by LDL or non-HDL cholesterol targets. The analysis also suggested the apoB-guided strategy could be cost-effective.
